GREENRISE GLOBAL BRANDS INC.

NOTICE OF CHANGE IN CORPORATE STRUCTURE Pursuant to Section 4.9(b)(iii) of National Instrument 51-102 Continuous Disclosure Obligations

1. NAME OF THE PARTIES TO THE TRANSACTION

Greenrise Global Brands Inc. (the "**Company**") (formerly AMP Alternative Medical Products Inc.) AIC040 UG ("**AIC**").

2. DESCRIPTION OF THE TRANSACTION

On November 3, 2021, the Company announced that it had entered into a share purchase agreement dated November 2, 2021, pursuant to which the Company acquired all of the issued and outstanding shares of Greenrise GmbH ("**Greenrise**") from AIC, the sole shareholder of Greenrise, in consideration for 4,290,000 Class A Voting Common Shares without par value of the Company (the "**Common Shares**") at a deemed price of \$0.34 per Consideration Share (the "**Acquisition**").

Concurrently with the closing of the Acquisition, the Company added Hendrik Knopp to the board of directors of the Company and Florian Witt and Alex Hintz as Chief Operating Officer and Chief Production Officer, respectively, all of whom were previously with Greenrise.

In connection with the Acquisition, Company changed its name from "AMP Alternative Medical Products Inc." to "Greenrise Global Brands Inc.". The Common Shares commenced trading on the Canadian Securities Exchange under its new name as of the open of trading on November 8, 2021. The Company's new CUSIP number is 39540L108 and its new ISIN number is CA39540L1085. The Company's trading symbol on the CSE will not change.

Further details regarding the Acquisition are set out in the Company's news release dated November 3, 2021, a copy of which is available under the Company's issuer profile on SEDAR at www.sedar.com.

3. EFFECTIVE DATE OF THE TRANSACTION

November 2, 2021.

4. NAMES OF EACH PARTY THAT CEASED TO BE A REPORTING ISSUER AFTER THE TRANSACTION AND OF EACH CONTINUING ENTITY

N/A

5. DATE OF REPORTING ISSUER'S FIRST FINANCIAL YEAR END AFTER THE TRANSACTION

Not required, as sections 4.9(a) and 4.2(b)(ii) of National Instrument 51-102 – *Continuous Disclosure Obligations* do not apply.

6. THE PERIODS, INCLUDING COMPARATIVE PERIODS, IF ANY, OF THE INTERIM FINANCIAL REPORTS AND THE ANNUAL FINANCIAL STATEMENTS REQUIRED

TO BE FILED FOR THE REORTING ISSUER'S FIRST FIANNCIAL YEAR AFTER THE TRANSACTION.

Not required, as sections 4.9(a) and 4.2(b)(ii) of National Instrument 51-102 – *Continuous Disclosure Obligations* do not apply.

7. DOCUMENTS FILED UNDER NATIONAL INSTRUMENT 51-102

Not required, as sections 4.9(a) and 4.2(b)(ii) of National Instrument 51-102 – *Continuous Disclosure Obligations* do not apply.

DATED the 10th day of December, 2021.